Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Intravenous replacement of fluid and electrolyte losses,Maintenance fluid therapy,Correction of metabolic acidosis (due to acetate and gluconate precursors of bicarbonate)
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable as a fixed pharmacokinetic parameter; dextrose half-life ~10 minutes (rapidly metabolized); electrolytes distribute and are cleared according to renal function. In patients with normal renal function, elimination half-life of water and electrolytes varies with hydration status and GFR.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle, releasing energy. Electrolytes are not metabolized; they are excreted renally or utilized in physiological processes.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal elimination of water and electrolytes; dextrose is metabolized to CO2 and water, with <1% excreted unchanged in urine. Sodium and potassium are primarily excreted renally; acetate is metabolized to bicarbonate and excreted via lungs as CO2.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
None for dextrose, sodium, potassium, chloride; acetate minimally bound (<10% to albumin).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Dextrose: ~0.2 L/kg (total body water); sodium: ~0.6 L/kg (extracellular fluid); potassium: ~0.6 L/kg (total body water but primarily intracellular). Vd corresponds to total body water for electrolyte components.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
100% bioavailability via intravenous route.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Contraindicated in patients with anuria or severe renal impairment (e GFR < 30 m L/min/1.73 m²). For mild to moderate impairment (e GFR 30-89 m L/min/1.73 m²), monitor serum potassium and renal function; adjust infusion rate based on fluid and electrolyte status.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific Child-Pugh based dose adjustment required. Use with caution in patients with severe hepatic impairment due to risk of fluid overload and electrolyte imbalances; monitor serum sodium and potassium.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion; dose based on weight and clinical condition. Typical rate: 5-20 m L/kg as a single dose, not to exceed 50 m L/kg/day. Adjust based on serum electrolyte levels and fluid balance.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution due to increased risk of fluid overload, renal impairment, and electrolyte disturbances. Initiate at lower infusion rates and monitor renal function, serum electrolytes, and volume status closely.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None.
None
Avoid in patients with hyperglycemia, severe renal impairment, or anuria,Monitor serum electrolytes and glucose levels during administration,Use with caution in patients with heart failure, renal disease, or those receiving corticosteroids,Risk of fluid overload and electrolyte imbalances,Do not administer unless solution is clear and container is intact
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hyperglycemia,Severe renal impairment (anuria or oliguria),Hypersensitivity to any component,Patients with elevated lactate levels or lactic acidosis
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No direct food interactions; however, dextrose content may affect blood glucose. Patients on a glucose-restricted diet should be monitored. No specific dietary restrictions required during administration.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregnancy, hyperglycemia or electrolyte imbalances may harm the fetus. First trimester: No known structural teratogenicity; second and third trimesters: Potential for fetal hyperglycemia, hyperinsulinemia, and electrolyte disturbances if maternal levels are not controlled. Use only if clearly needed.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
ISOLYTE S IN DEXTROSE 5% components are endogenous and excreted into breast milk in varying amounts. Dextrose is normal milk sugar; electrolytes are present in milk. No adverse effects on nursing infants are expected at therapeutic doses. M/P ratio: Not established for the combination; individual electrolytes and dextrose have high milk/plasma ratios but are physiologic. Use with caution.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustments required for pregnancy per se. However, increased plasma volume in pregnancy may alter distribution; monitor response and adjust rate based on clinical status, fluid balance, and laboratory values.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
ISOLYTE S in 5% Dextrose is a balanced electrolyte solution with 5% dextrose for maintenance fluid therapy. Monitor serum glucose closely, especially in diabetic patients. The solution provides potassium, magnesium, and phosphate; avoid in severe hyperkalemia, hypermagnesemia, or hyperphosphatemia. Contains acetate as a bicarbonate precursor; use with caution in patients with metabolic alkalosis. Do not administer with blood products due to risk of hemolysis. Incompatible with many drugs; confirm compatibility prior to Y-site administration.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This fluid contains sugar (dextrose) and electrolytes to maintain your body's balance.,Tell your healthcare provider if you have diabetes, as this may affect your blood sugar.,Report any signs of allergic reaction: rash, itching, swelling, or difficulty breathing.,Notify your nurse if you experience pain, redness, or swelling at the IV site.,This solution is provided in a plastic container; do not remove from the overwrap until ready to use.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S in Dextrose 5% is a combination of electrolytes and dextrose. Dextrose provides caloric support and helps correct hypoglycemia. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) replenish fluid and electrolyte deficits, maintaining osmotic balance and acid-base homeostasis.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by clinical condition, fluid and electrolyte requirements. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate not exceeding 50 m L/kg/day.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE S IN DEXTROSE 5% is an electrolyte and carbohydrate solution. No specific teratogenic effects are associated with the components at therapeutic doses. However, during pregn. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.